Skip to content

Trial Summary

As you are going to be treated with chemoradiation therapy for your head and neck cancer, you will most likely develop oral mucositis. As such this study is testing an experimental treatment for oral mucositis. This experimental treatment is called ST-617.

Acronym:

ST 617-101

ACTRN/NCT /ethics:

ACTRN12620000541909

Scientific title:

A Phase 1b, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ST-617 for the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for Head and Neck Cancer

Sponsor / Cooperative group:

Supportive Therapeutics (Pty) Ltd

Trial & Patient Characteristics

Cancer TypeHead and Neck
Trial TypeTreatment
PhasePhase I; Phase II
Age Range18 years and older
SexBoth
Tumour Stream Head and Neck
Cancer StageAll stages
Anticipated Start Date2019-11-12
Anticipated End Daten/a

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Emailalex.scott-hoy@sa.gov.au
Phone08 8204 4830
Principal InvestigatorDr Shawgi Sukumaran
Recruitment StatusRecruiting
HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorDr Hien Le
Recruitment StatusRecruiting